4/22
04:06 pm
mirm
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value [Seeking Alpha]
4/17
03:01 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.
4/10
09:30 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
12:04 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
4/2
08:39 am
mirm
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome [Yahoo! Finance]
4/2
08:30 am
mirm
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Low
Report
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
3/29
12:57 pm
mirm
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/21
06:41 am
mirm
Mike Grey appointed Executive Chair of Theolytics' Board of Directors [Yahoo! Finance]
Low
Report
Mike Grey appointed Executive Chair of Theolytics' Board of Directors [Yahoo! Finance]
3/18
03:10 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at HC Wainwright from $45.00 to $58.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at HC Wainwright from $45.00 to $58.00. They now have a "buy" rating on the stock.
3/18
02:49 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at SVB Leerink LLC from $44.00 to $43.00. They now have an "outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at SVB Leerink LLC from $44.00 to $43.00. They now have an "outperform" rating on the stock.
3/15
11:05 am
mirm
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use [Yahoo! Finance]
Medium
Report
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use [Yahoo! Finance]
3/13
06:53 pm
mirm
US FDA approves expanded use of Mirum's liver disease drug [Reuters]
Medium
Report
US FDA approves expanded use of Mirum's liver disease drug [Reuters]
3/13
06:03 pm
mirm
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis [Yahoo! Finance]
3/13
06:00 pm
mirm
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Medium
Report
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
3/8
07:30 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5
08:23 am
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/5
08:00 am
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
3/5
05:38 am
mirm
Mirum Pharmaceuticals: Advancing On Several Key Fronts [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals: Advancing On Several Key Fronts [Seeking Alpha]
2/29
03:42 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at HC Wainwright from $58.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at HC Wainwright from $58.00 to $45.00. They now have a "buy" rating on the stock.
2/29
02:34 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.
2/29
02:34 pm
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at JMP Securities from $64.00 to $69.00. They now have a "market outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at JMP Securities from $64.00 to $69.00. They now have a "market outperform" rating on the stock.
2/29
12:55 pm
mirm
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat [Yahoo! Finance]
Low
Report
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat [Yahoo! Finance]
2/29
10:05 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
08:40 am
mirm
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI [Yahoo! Finance]
Low
Report
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI [Yahoo! Finance]
2/29
08:30 am
mirm
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Low
Report
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI